Manidipine Teva (Manidipine Dihydrochloride)

Manidipine blocks L‑type calcium channels on vascular smooth‑muscle cells, preventing calcium entry that drives muscle contraction. This causes relaxation of arterial walls, leading to vasodilation and a decrease in peripheral vascular resistance, which in turn lowers blood pressure.

The appropriate dose of Manidipine Teva is determined by the prescribing clinician based on the individual’s blood pressure, response to therapy, and any co‑existing medical conditions. The prescriber will select an initial dose and adjust it as needed to achieve target blood pressure.

Manidipine is generally not recommended for use during pregnancy or while breastfeeding because safety data are limited. Healthcare providers usually consider alternative antihypertensive agents with established safety profiles for pregnant or lactating patients.

To order Manidipine Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Manidipine belongs to the dihydropyridine class of calcium channel blockers, offering potent vasodilation with a relatively low incidence of reflex tachycardia compared with some alternatives. Compared with agents such as amlodipine, it may provide a smoother blood‑pressure profile, but the choice of therapy depends on individual patient characteristics and physician judgment.

Manidipine tablets should be stored at room temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Manidipine is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water and follow any specific timing instructions provided by the healthcare professional.

The most serious risks include severe hypotension, which can cause fainting or organ hypoperfusion, allergic reactions such as anaphylaxis, and rare cases of liver injury. Patients should seek immediate medical attention if they experience symptoms like sudden dizziness, rash, swelling, or jaundice.

Manidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation, in those with severe hypotension or cardiogenic shock, and in individuals with certain severe cardiac conditions where rapid blood‑pressure reduction could be harmful.